LLY Eli Lilly and Co
- 734.970
- -20.940-2.77%
- 738.000
- +3.030+0.41%
Eli Lilly and Co News
Top 20 Turnover | Apple surged 6% after announcing a $110 billion share repurchase plan
On Friday, Nvidia, No. 1 in terms of US stock turnover, closed 3.46% higher, with a transaction of US$35.189 billion; No. 2 Apple closed 5.98% higher, with a transaction of US$30.13 billion; and Tesla, number 3, closed 0.66% higher, with a transaction of US$13.683 billion.
Options -- The Striking Price: An Options Strategy That Takes the Long View -- Barron's
By Steven M. Sears There are certain financial facts made truer by time. Never let transitory market drama make you forget that. Compound interest, which some have called the eighth wonder of the wo
US stocks closed | NASDAQ rose about 2%, Apple surged 6% after the results, and Nvidia rose more than 3%
The three major US stock indexes closed up at least 1%; Amgen led the S&P and Dow, the diet drug duo Lilai once fell more than 3%, and Novo Nord Europe shares once fell more than 5%; the chip stock index closed up more than 2% and still fell throughout the week. Qualcomm's sharp rise fell back the next day, and AMD earnings fell more than 4% in the week
Amazon Stock Is on a Roll. Here's Why It's on This Firm's 'Best Ideas List.' -- Barrons.com
These reports, excerpted and edited by Barron's, were issued recently by investment and research firms. The reports are a sampling of analysts' thinking; they should not be considered the views or rec
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Weight-loss Drug Competition Heats Up. Is Wegovy in Trouble?
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Amgen Stock Soars on Weight Loss Injection Progress as Novo Nordisk, Eli Lilly Shares Slide
Amgen's stock jumped on Friday after the drugmaker teased positive initial data on its experimental weight loss injection. That fueled investor concerns about new competition in the rapidly going weight loss drug industry, sending shares of Novo Nordisk and Eli Lilly lower on Friday. Novo Nordisk's stock was already under pressure after sales of its blockbuster weight loss injection Wegovy missed analysts' estimates for the first quarter.
Changes in US stocks 丨 Lilly fell 3%, and the mid-term trial of Amgen's new weight loss drug received positive data
May 3 | LLY.US (LLY.US) fell 3% to $733.27. According to the news, the mid-term trial of Amgen's new weight loss drug has received positive data. If the drug is approved, it will compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Earlier, some media said that Amgen is testing a new weight loss drug. The mechanism of action is different from Novo Nordisk and Eli Lilly's products, which can cause patients to lose weight even if they stop taking the medication.
Amgen Stock Rallies 13% on GLP-1 Weight-loss Drug Update
Amgen Knocks Novo Nordisk's Ozempic Stock Rally -- WSJ
By Chelsey Dulaney Amgens progress on its experimental weight-loss drug offered investors a reminder that Novo Nordisk isnt the only game in town. That is bad news for the Danish company's high-flyin
Is the competitive landscape changing? Amgen's mid-term trial of a new weight loss drug received positive data, and the stock price soared
Amgen's CEO said he was “very encouraged” by the initial findings of the company's experimental weight loss drug MariTide, which boosted the company's stock price.
Most of the US diet drug concept stocks rose at the beginning of the market. Anjin rose 13.8%, Shuodi Biotech's ADR rose 1.4%, Bojian BIIB rose 0.9%, ETF HRTS rose 0.8%, Forte Pharmaceuticals rose 0.1%, Novo Nordisk ADR fell 1%, Viking Therapeutics fell 1
Most of the US diet drug concept stocks rose at the beginning of the market. Anjin rose 13.8%, Shuodi Biotech's ADR rose 1.4%, Bojian BIIB rose 0.9%, ETF HRTS rose 0.8%, Forte Pharmaceuticals rose 0.1%, Novo Nordisk ADR fell 1%, Viking Therapeutics fell 1.4%, and Lilly Pharmaceuticals fell 2%.
Express News | US stocks rose collectively at the beginning of the session. The Dow rose 1.34%, the NASDAQ rose 1.94%, and the S&P 500 index rose 1.25%. The number of US non-farm payrolls fell far short of expectations in April. The exchange market expects the Federal R
Amgen 'Very Encouraged' by Data From Weight-loss-drug Trial, as Stock Jumps
By Claudia Assis Amgen's stock soars toward biggest gain in 15 years, would add more than 220 points to the Dow's price Shares of Amgen Inc. soared in premarket trading Friday, after the drug manufa
US STOCKS-Wall St Set to Open Sharply Higher on Soft Jobs Data
Lilly and Novo Nordisk Shares Are Trading Lower Following a Weight Loss Drug Update From Amgen.
Lilly and Novo Nordisk Shares Are Trading Lower Following a Weight Loss Drug Update From Amgen.
Express News | Amgen US stocks surged more than 14% ahead of the market, and the mid-term trial of its new weight loss drug received positive data. If the drug is approved, it will compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
US STOCKS-Futures Rise on Apple, Amgen Boost; Jobs Data Awaited
Analysis
Price Target
No Data
